Iclusig

Active Ingredient(s): Ponatinib
FDA Approved: * December 14, 2012
Pharm Company: * ARIAD PHARMACEUTICALS
Category: Cancer

Ponatinib (trade name Iclusig /aklus/ eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.[2] Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Iclusig 30 mg Oral Tablet, Film Coated
NDC: 63020-533
Labeler:
Millenium Pharmaceuticals Inc.
Iclusig 45 mg Oral Tablet, Film Coated
NDC: 63020-534
Labeler:
Millenium Pharmaceuticals Inc.
Iclusig 15 mg Oral Tablet, Film Coated
NDC: 63020-535
Labeler:
Millenium Pharmaceuticals Inc.
Iclusig 10 mg Oral Tablet, Film Coated
NDC: 63020-536
Labeler:
Millennium Pharmaceuticals, Inc.
Iclusig 30 mg Oral Tablet, Film Coated
NDC: 76189-533
Labeler:
Ariad Pharmaceuticals, Inc.
Iclusig (As Ponatinib Hydrochloride) 45 mg Oral Tablet
NDC: 76189-534
Labeler:
Ariad Pharmaceuticals, Inc.
Iclusig (As Ponatinib Hydrochloride) 15 mg Oral Tablet
NDC: 76189-535
Labeler:
Ariad Pharmaceuticals, Inc.